Plexus Q2 FY2026 Call: Steady Execution, No Inflection Yet

What happened

Plexus reported its Q2 FY2026 results, with the earnings call transcript revealing revenue and margins within the guided range but not yet reflecting the acceleration to 9–12% growth that the market has priced in. Program wins remain robust at roughly $900M annualized, but churn and EMEA softness continue to offset gains, keeping top-line growth in the mid-single digits. Non-GAAP operating margin held near 5.8–6.0%, consistent with the report’s base case, while free cash flow tracked toward the guided ~$100M level. Management reiterated their long-term targets but offered no clear catalyst for a near-term inflection, leaving the stock’s premium multiple exposed to execution risk. The transcript confirms the thesis outlined in the DeepValue report: Plexus is a high-quality EMS provider, but its valuation already reflects the best-case scenario, and the data so far does not justify a rerating.

Implication

For existing holders, the Q2 transcript does not trigger a thesis change but reinforces the report's caution. The lack of a growth inflection means the stock remains vulnerable to multiple compression if guidance is not raised or if macro headwinds persist. Investors should monitor the next two quarters for evidence that program wins are converting into revenue acceleration. If growth stays below 5%, consider trimming positions toward the $150 attractive entry zone. For new investors, patience is warranted; wait for either a pullback to the $150 level or clear signs of a ramp before initiating or adding.

Thesis delta

No material shift from the report's base case. The Q2 results are consistent with the 'POTENTIAL SELL' thesis: revenue growth remains below the 9–12% target, margins are stable but not expanding, and free cash flow generation is modest. The transcript does not provide evidence that the bear case risks (EMEA weakness, churn, tax headwinds) are receding, nor does it introduce new bullish catalysts. The risk-reward skew remains to the downside at the current price of ~$181, and the re-assessment window of 6–12 months remains intact.